Product Description
Glutamine is the most abundant and versatile amino acid in the body. Glutamine is the most abundant and versatile amino acid in the body, and is of fundamental importance to intermediary metabolism, interorgan nitrogen exchange via ammonia (NH3) transport between tissues, and pH homeostasis. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266414/)
Mechanisms of Action: GLS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Intravenous
FDA Designation: Orphan Drug - *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Czech | Ecuador | Egypt | Estonia | Finland | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Korea | Latvia | Lebanon | Lithuania | Malaysia | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Emmaus Medical
Company Location: Western America
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Obstetric Labor, Premature|Acute Respiratory Distress Syndrome|Urinary Tract Infections|Malnutrition|Urinary Retention|Hematopoietic Stem Cell Transplant|Bone Marrow Transplantation|Colorectal Cancer|Gastrointestinal Cancer|Pneumonia|Lyme Disease|Depressive Disorder|Enteritis|Traumatic Brain Injury|Cystic Fibrosis|Breast Cancer|Other|Type 2 Diabetes|Hypothyroidism|Gastroenteritis|Insulin Resistance|Mucositis|Stomatitis|Intestinal Diseases|Anemia, Sickle Cell|Oxidative Stress|Inflammation
Phase 3: Malnutrition|Diarrhea|Neck Pain|Mucositis|Head and Neck Cancer|Surgical Wound Infection|Kidney Diseases|Respiratory Insufficiency|Pulmonary Valve Insufficiency|Heart Failure|Vision, Low|Weight Loss|Breast Cancer|Intestinal Diseases|Oxidative Stress|Inflammation|Peripheral Nervous System Diseases|Protein Deficiency|Esophagitis|Coronary Artery Disease|Myocardial Ischemia|Muscular Dystrophy, Duchenne|Breast Diseases|Sepsis|Proctitis|Colorectal Cancer|Other|Burns Unspecified|Thalassemia|Muscle Cancer|Oncology Unspecified|Overweight|Acute Kidney Injury|Hepatitis B|Cachexia|Carcinogenesis|Bone Cancer|Large Cell Carcinoma|Small Cell Lung Cancer|Melanoma|Eye Cancer|Anemia, Sickle Cell|beta-Thalassemia|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Esophageal Cancer|Weight Gain|Lung Injury|Hepatitis C|Smooth Muscle Tumor|Lactose Intolerance|Intestinal Cancer|Obesity|Obstetric Labor, Premature|Hepatitis, Animal|Nose Cancer|NUT Carcinoma|COVID-19
Phase 2: Coronary Artery Disease|Myocardial Ischemia|Insulin Resistance|Hyperglycemia|Rheumatic Heart Disease|Respiratory Aspiration of Gastric Contents|Peripheral Nervous System Diseases|Inflammation|Muscular Dystrophy, Duchenne|Transplantation Unspecified|Acquired Immunodeficiency Syndrome|Colorectal Cancer|Multiple Myeloma|Other|Stem Cell Transplant|Mucositis|Endometriosis|Generalized anxiety disorder|Breast Cancer|HIV Infections|Kidney Diseases|Clostridium Infections|Communicable Diseases|Anemia, Sickle Cell|Thalassemia|Injuries/wounds Unspecified|Kidney Failure, Chronic|Enteritis|Ileus|Hidradenitis Suppurativa|Diarrhea|Healthy Volunteers|Herpes Labialis|Prostate Cancer|Stomatitis|Head and Neck Cancer|Periodontitis|Herpes Simplex|Irritable Bowel Syndrome|Enterocolitis, Pseudomembranous|Dyspepsia|Leukemia|Hypertension, Pulmonary|Proctitis|Sarcoma|Cystic Fibrosis|Kidney Cancer|Lymphoma
Phase 1: Lymphangioleiomyomatosis|Type 2 Diabetes|Injuries/wounds Unspecified|Acidosis|Inflammation|Propionic Acidemia|Breast Cancer|Dermatitis, Atopic|Adenocarcinoma|Pancreatic Cancer|Peripheral Nervous System Diseases|Breast Diseases|Pancreatic Ductal Carcinoma|Head and Neck Cancer|Traumatic Brain Injury|Colorectal Cancer|Diverticulosis, Colonic|Squamous Cell Carcinoma|Oncology Solid Tumor Unspecified|Generalized anxiety disorder|Colonic Diseases|Crohn Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06291038 |
MISSISIIPI | N/A |
Not yet recruiting |
Irritable Bowel Syndrome |
2029-03-01 |
2024-03-05 |
Primary Endpoints|Treatments |
|
ChiCTR2500108082 |
ChiCTR2500108082 | N/A |
Not yet recruiting |
Colorectal Cancer |
2028-08-19 |
|||
ChiCTR2500103114 |
ChiCTR2500103114 | N/A |
Not yet recruiting |
Pancreatic Cancer |
2027-05-20 |
|||
NCT04623502 |
STU-2019-1061 | N/A |
Recruiting |
Renal Cell Carcinoma|Kidney Cancer|Transitional Cell Carcinoma|Papillary Carcinoma|Leiomyomatosis|Papillary Adenocarcinoma|Clear Cell Adenocarcinoma |
2027-04-30 |
2026-01-29 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT04785989 |
Chronic Lymphocytic Leukemia | N/A |
Recruiting |
Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia |
2026-10-01 |
2025-10-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT06027242 |
202207099RINA | N/A |
Recruiting |
Gastrointestinal Cancer |
2026-08-30 |
2023-09-09 |
Primary Endpoints|Start Date|Treatments |
|
NCT05972291 |
SPLD-006-22F | N/A |
Recruiting |
Irritable Bowel Syndrome |
2026-07-30 |
2023-10-27 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT04883515 |
OBEGLUT | N/A |
Recruiting |
Obesity|Intestinal Diseases|Insulin Resistance |
2026-06-01 |
2026-02-10 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
ChiCTR2400082676 |
ChiCTR2400082676 | N/A |
Not yet recruiting |
Heart Failure |
2026-04-02 |
2024-04-03 |
Treatments |
|
NCT06328283 |
Soh-Med-24-02-01MD | N/A |
Not yet recruiting |
Hepatocellular Carcinoma |
2026-03-01 |
2024-03-26 |
Primary Endpoints|Treatments |
|
NCT03384108 |
NCT03384108 | N/A |
Recruiting |
Healthy Volunteers |
2026-01-01 |
2024-04-10 |
Primary Completion Date|Primary Endpoints |
|
ChiCTR2500102350 |
ChiCTR2500102350 | N/A |
Recruiting |
Pulmonary Heart Disease|Tetralogy of Fallot|Pulmonary Atresia |
2025-12-31 |
|||
CTR20252983 |
CTR20252983 | N/A |
Completed |
Gastritis|Duodenal Ulcer |
2025-10-16 |
2025-11-09 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20252754 |
CTR20252754 | N/A |
Completed |
Duodenal Ulcer|Gastritis |
2025-10-01 |
2025-12-28 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT07220447 |
NCI-2025-05686 | P1 |
Recruiting |
Generalized anxiety disorder|Oncology Solid Tumor Unspecified |
2027-07-09 |
2026-02-13 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT03275974 |
NCI-2017-01543 | P1 |
Terminated |
Colorectal Cancer |
2025-12-23 |
2026-01-03 |
Primary Completion Date|Primary Endpoints |
|
2024-516595-15-00 |
HidraQureS/2020 | P2 |
Not yet recruiting |
Hidradenitis Suppurativa |
2027-09-27 |
2025-05-02 |
Treatments |
|
NCT04305769 |
ACT | P2 |
Recruiting |
Enterocolitis, Pseudomembranous|Diarrhea|Clostridium Infections |
2026-12-31 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT07053761 |
NCT07053761 | P2 |
Not yet recruiting |
Proctitis |
2026-06-30 |
2025-07-09 |
Primary Endpoints |
|
NCT07020754 |
FUE.REC25/8-2025 | P2 |
Completed |
Mucositis|Stomatitis|Head and Neck Cancer |
2026-01-01 |
2026-01-31 |
||
NCT05655819 |
NCT05655819 | P2 |
Completed |
Dyspepsia |
2025-12-31 |
2026-02-04 |
Primary Endpoints|Treatments|Trial Status |
|
NCT06617182 |
KY20242229-F-1 | P2 |
Not yet recruiting |
Enteritis |
2025-10-01 |
2024-09-28 |
||
NCT07287592 |
FMASU R 146/2021 | P3 |
Not yet recruiting |
Oncology Unspecified |
2026-12-30 |
2025-12-18 |
Primary Endpoints|Treatments |
|
NCT05852990 |
CEI/1565/21 INCAN/CEI/0074/22 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer|Diarrhea |
2025-12-01 |
2025-05-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
ACTRN12625000561482 |
ACTRN12625000561482 | P4 |
Not yet recruiting |
Hypothyroidism |
2025-07-30 |
2025-06-10 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/30/2025 |
News Article |
Emmaus Life Sciences Announces Strategic Transaction |
|
12/11/2025 |
News Article |
"I Have More Energy, Sleep Better, and Better Elimination" - Gundry MD Total Restore Earns Rave Reviews for Transforming Gut Health |
|
12/04/2025 |
News Article |
Pusan National University Researchers Identify the Brain Enzyme That Drives Nicotine Addiction and Smoking Dependence |
|
12/01/2025 |
News Article |
Youth Switch Longevity Supplement Features Clinically Studied Ingredients for Aging Markers |